Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — Corporate Update (September 2025)
11 slides from Bcal Diagnostics's corporate update, September 2025
Slide 1: Investor Update: ClearNote Health Partnership
SEPTEMBER 2025 Investor Update ClearNote Health Partnership
Slide 2: BCAL and ClearNote Health partnership
BCAL and ClearNote Health partnership ClearNote Health has selected BCAL to deliver their cutting-edge early detection cancer tests in Australia and New Zealand BCAL has exclusive rights to distribute ClearNote’s Avantect Pancreatic and Avantect Ovarian tests in Australia and New Zealand Initial ter
Slide 3: Who is ClearNote Health?
Who is ClearNote Health? History Technology leader Global validation • ClearNote Health is a US based • Virtuoso epigenomics platform • CLIA/CAP-accredited lab in San company transforming cancer powered by AI & bioinformatics Diego, UKCA-marked in the UK. detection through early, accurate, used by N
Slide 4: Pancreatic cancer: highly lethal, or just hidden?
Pancreatic cancer: highly lethal, or just hidden? 5-year relative survival for 3% distant pancreatic cancer1 VS 68.3% 90+%* 96.9% (95% CI:51.9-81.9) (95% CI:96-97.6) >80% 5-year survival at stage 1A1 Sensitivity (Stages I+II) Specificity Today, survival rates are extremely unlikely as most pancreati
Slide 5: Ovarian cancer: early detection saves lives
Ovarian cancer: early detection saves lives 7 out of 10 women are diagnosed Women diagnosed early have at advanced stage III/IV far better outcomes 32% Stage IV survival rate1 92% Stage 0 - IIA survival rate2 Initial Independent Analytical Validation % Value (95% CI) Number of Samples Sensitivity (I
Slide 6: Large addressable markets for early detection
Large addressable markets for early detection With large potential markets and positive gross margins from Day 1, minimal market penetration can have outsized financial impact. Avantect Pancreas Avantect Ovarian Avantect Multi-cancer • Genetic mutations (BRCA1, • Genetic mutations (BRCA1, • Genetic
Slide 7: Excellent alignment between BREASTEST Plus and Avantect
Excellent alignment between BREASTEST Plus and Avantect Agreement solidifies BCAL Diagnostics as a leading expert in early- Cutting edge, early-stage stage cancer detection cancer detection expertise Agreement creates additional in-licensing opportunities for complementary tests from other providers
Slide 8: What does this mean for BCAL?
What does this mean for BCAL? Market leadership Positions BCAL as a leader in blood-based multi-cancer screening in Australia & New Zealand. Broadened portfolio Adds pancreatic and ovarian cancer tests to complement BCAL’s breast cancer program. Strategic leverage Uses existing clinician and partner
Slide 9: Key takeaways
Key takeaways Agreement is a major endorsement of BCAL’s commercial capability. ClearNote selection of BCAL as their exclusive path to market in Australia and New Zealand demonstrates belief in BCAL to generate revenue for both parties based on their extensive clinical network and commercial capabil
Slide 10: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by BCAL Diagnostics The forward-looking statements are based on information available to BCAL Not An Offer Ltd ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change and the This Presentati
Slide 11: Jayne Shaw Executive Chair Jshaw@bcaldiagnostics.com
20XX Jayne Shaw Shane Ryan Executive Chair Chief Executive Officer Jshaw@bcaldiagnostics.com Sryan@bcaldiagnostics.com 11